Table 1.

Generalities and patient baseline of the included studies (FU follow-up)

Author and year	Journal	Last FU (months)	Drug	Daily administration	Patients (n)	Mean age	Women (%)	Mean BMI (kg/m2)
Anderson et al. 2018 [16]	N Engl J Med	3	Aspirin	100	1707	63	51%	27
			Rivaroxaban	20	1717	63	50%	28
Eriksson et al. 2001 [37]	Orthopedics	2	Fondaparinux	2.5	849	65	70%	27
			Enoxaparin	40	862	65	67%	27
Eriksson et al. 2004 [38]	J Thumb Haemost	3	Ximelagatran	2	1377	67	65%	27
			Enoxaparin	40	1378	67	64%	27
Eriksson et al. 2006 [39]	J Thumb Haemost	2	Rivaroxaban	2.5	135	64	64%	28
			Rivaroxaban	5	139	65	54%	39
			Rivaroxaban	10	138	65	62%	28
			Rivaroxaban	20	137	66	57%	28
			Rivaroxaban	30	37	64	59%	29
			Enoxaparin	40	132	80	59%	28
Eriksson et al. 2006 [40]	Circulation	2	Rivaroxaban	5	128	84	56%	27
			Rivaroxaban	10	142	79	63%	27
			Rivaroxaban	20	139	69	59%	27
			Rivaroxaban	30	142	77	51%	27
			Rivaroxaban	40	137	80	59%	27
			Enoxaparin	40	157	80	64%	27
Eriksson et al. 2007 [41]	Thromb Res	2	Rivaroxaban	20	68	67	65%	27
			Enoxaparin	40	162	66	54%	28
			Rivaroxaban	5	76	64	62%	28
			Rivaroxaban	10	80	67	64%	28
			Rivaroxaban	30	88	66	58%	28
			Rivaroxaban	60	74	64	54%	28
			Rivaroxaban	40	77	66	58%	28
Eriksson et al. 2008 [42]	N Engl J Med	3	Rivaroxaban	10	2209	70	55%	28
			Enoxaparin	40	2224	69	54%	28
Eriksson et al. 2011 [43]	BMJ	3	Dabigatran	220	1010	72	53%	27
			Enoxaparin	40	1003	72	50%	27
Fuji et al. 2014 [44]	J Arthoplasty	3	Edoxaban	15	78	61	80%	26
			Edoxaban	30	72	60	95%	26
			Enoxaparin	40	74	58	79%	26
Fuji et al. 2015 [45]	Thromb J	3	Edoxaban	30	220	62	86%	25
			Enoxaparin	20	212	62	85%	25
Kakkar et al. 2008 [46]	Lancet	1	Rivaroxaban	10	1228	70	54%	26
			Enoxaparin	40	1229	71	53%	27
Lassen et al. 2010 [47]	N Engl J Med	4	Apixaban	5	2708	60	52%	28
			Enoxaparin	40	2699	60	53%	28
Lassen et al. 2002 [56]	Lancet	2	Fondaparinux	2.5	1140	66	57%	26
			Enoxaparin	40	1130	67	58%	27
Rascob et al. 2012 [49]	J Bone Joint Surg Br	3	Apixaban	5	2708	61	53%	28
			Enoxaparin	40	2699	61	54%	28